As burn injuries rise from combat, disasters, and industrial accidents, one company’s enzymatic product has become so effective that the U.S. government is buying and stockpiling it for national emergencies.
MediWound (Nasdaq: MDWD) isn’t your typical biotech. Its product NexoBrid, an FDA-approved burn treatment, can clear away dead tissue in hours without surgery. That ability has made it an important part of America’s emergency medical preparedness program: it is funded and stockpiled by BARDA, the U.S. government’s biodefense and emergency-preparedness agency, and is backed by the Department of Defense, which is funding the development of a new battlefield-ready, temperature-stable formulation.
From the Hospital to the Battlefield
When mass-casualty burn events strike, surgical capacity becomes the bottleneck. NexoBrid helps relieve that pressure. Instead of scalpels, its plant-based enzymes dissolve dead tissue while preserving healthy skin, often reducing the need for surgical debridement.
The treatment has already been used in around 60 U.S. burn centers, building on data from over 230 patients treated under expanded-access and emergency-use protocols that showed consistent results: rapid eschar removal and reduced need for surgical excision. During the Israel-Hamas conflict, doctors also reported successful use of NexoBrid in treating severe civilian burn injuries, reinforcing its real-world performance under crisis conditions.
That real-world proof is exactly why the U.S. government made MediWound part of its national readiness plan. BARDA funded both development and procurement of NexoBrid for U.S. emergency preparedness with over $120 million. Meanwhile, the Department of Defense is financing a room-temperature-stable version that can withstand harsh battlefield conditions – critical when refrigeration isn’t possible. This isn’t theoretical support; it’s stockpiling and product development, the kind of validation few small-cap biotechs ever achieve.
Beyond Defense: Commercial Growth and Scale-Up
While the government funds readiness, commercial demand is also building. MediWound’s U.S. partner Vericel recently reported strong NexoBrid growth, with U.S. NexoBrid revenue increasing 207% year-over-year, and the highest number of hospital unit orders in any month since launch. At the same time, management and analysts point to global demand outpacing existing manufacturing capacity, which is driving a major scale-up effort.
To meet this need, the company has completed commissioning of a new facility in Israel that is expected to increase NexoBrid output approximately six-fold and reach full operational readiness by year-end 2025, supporting both defense and civilian supply chains across 45 approved countries.
The company’s second product, EscharEx®, aims to bring the same enzymatic precision to chronic wounds such as diabetic foot ulcers (DFU) and venous leg ulcers (VLU) – a market estimated above $2.5 billion. In a controlled Phase 2 trial, EscharEx achieved 63% complete debridement in two weeks compared to 0% with SANTYL®, the decades-old market leader. Median time to debridement was nine days, versus “not achieved” with SANTYL over the study period.
That level of efficacy has drawn attention from major global wound-care players. MediWound is advancing its global VALUE Phase 3 VLU study for EscharEx with support from industry partners including Mölnlycke, Essity, Solventum (3M spinoff) and MiMEDX, in parallel to their DFU study which is being supported by the European Innovation Council and Kerecis (Coloplast).
A Strategic Asset with Real Momentum
MediWound has also strengthened its balance sheet with recent non-dilutive funding from BARDA, the European Innovation Council, and the U.S. Department of Defense, alongside new equity financing to support its manufacturing expansion and late-stage trials. Combined with recurring revenue from NexoBrid and long-term BARDA procurement, the company is scaling from a position of increasing financial flexibility.
Few small-cap biotechs ever reach this level of government validation. NexoBrid isn’t just a hospital innovation—it’s a strategic medical countermeasure that Washington is actively funding, stockpiling, and adapting for the field. And with a second product poised to enter a multibillion-dollar chronic wound market, MediWound is building a platform that bridges biotechnology, national security, and commercial scale.
The story is simple but rare: a small company creating technology powerful enough that governments rely on it in emergencies, with significant commercial potential still ahead.
Subscribe for Similar Reports
Read More from The Finance Herald
- Bizarre Connections: The Alarming Ties Between Jeffrey Epstein and Bill Gates in Pandemic Preparedness
- After Big Pharma Validated KRAS, an Under the Radar Microcap Is Approaching Human Trials in Pancreatic Cancer
- Greenland at the Center of a New Geopolitical Landscape: The Race for Arctic Power
- Inspira Technologies: A Micro-Cap MedTech Play With Unusual Commercial Momentum
- Scandal at the Top: Paul Weiss Chairman Brad Karp Resigns Over Epstein Emails
- Entera Bio Accelerates Its Hypoparathyroidism Program as a Catalyst-Heavy Year Takes Shape
- A New Trade Era: India’s Bold Shift Towards American Economic Partnership and Its Global Implications
- The Silent Insurrection: How Coordinated Activism Threatens America’s Future
Disclaimer & Disclosure: This content is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from MediWound Ltd for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details and information regarding the operator of Wall Street Wire alongside the full disclaimers and disclosures this content is subject to are available here: wallstwire.ai/disclosures. We are not responsible for any market size figures that may be cited in this article nor do we endorse them, they are quoted based on publicly available news reports and additional price targets or figures may exist that may not have been quoted. This article should not be considered an official communication by the issuer.